Oncocyte (OCX) filed a registration statement Friday for the resale of up to around 10.6 million shares of its common stock by a selling shareholders from time to time.
About 7.5 million shares for resale were issued in a private placement, while around 3.1 million shares are issuable upon the exercise of pre-funded warrants.
The company said it will not receive any proceeds from the sale of the shares.
It will receive the applicable proceeds from the exercise of the pre-funded warrants, if they are exercised for cash, at an exercise price of $0.001 per share. Oncocyte said it intends to use those proceeds, if any, for general corporate purposes.
Price: 3.04, Change: -0.17, Percent Change: -5.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。